Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $61
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $57 to $61.
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $57 to $61.